A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases
A "Classic" Ketogenic Diet as a Complementary Therapeutic Management on Patients With High-grade Gliomas and Brain Metastases.
Attikon Hospital
15 participants
Sep 20, 2022
INTERVENTIONAL
Conditions
Summary
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.
Eligibility
Inclusion Criteria5
- Age 18-80
- Karnofsky Performance Score of 50 or more.
- Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.
- Normal function of liver and kidneys
- Ability to sign informed consent form
Exclusion Criteria6
- Diabetes mellitus
- Life expectancy \>3 months
- Inability to adhere to diet
- Inability to give informed consent form
- Cholecystectomy last 1 year (before the study entry)
- Diagnosis of genetic disorder of fat metabolism
Interventions
Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05564949